Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 5/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.37 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | PDE5A | O76074 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | PDE1A | P54750 | 2/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.34 |
| ▸ | KHK | P50053 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883909 | 0.91 | TNKS (0.37) | TNKSTNKS2PARP1PDE5APDE2A | |
| SCHEMBL5884367 | 0.91 | PDE5A (0.45) | TNKSTNKS2PARP1PDE5APDE1A | |
| SCHEMBL5859643 | 0.88 | ADORA2B (0.39) | TNKSTNKS2PARP1PDE5ARAB9A | |
| SCHEMBL5729050 | 0.85 | ALDH1A1 (0.38) | TNKS2PDE5ASMN1; SMN2PDE1APDE1B | |
| SCHEMBL5884299 | 0.83 | PIN1 (0.37) | PDE5APDE2A | |
| SCHEMBL5884374 | 0.83 | NPC1 (0.37) | PARP1PDE5ARAB9ASMN1; SMN2PDE1A | |
| SCHEMBL5883954 | 0.83 | MEN1 (0.38) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5883866 | 0.80 | PDE5A (0.41) | TNKS2PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5731169 | 0.78 | ADORA2A (0.37) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5884419 | 0.78 | PDE5A (0.50) | TNKSTNKS2PARP1PDE5APDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087605-B2 | 5-Ethyl-imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| EP-1397363-B1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | EPX, TPMT, IL5 | TNKS 1300/4885TNKS2 1927/4885PARP1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.